Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama cut its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 0.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 188,567 shares of the specialty pharmaceutical company’s stock after selling 1,510 shares during the quarter. Retirement Systems of Alabama owned approximately 0.31% of Jazz Pharmaceuticals worth $23,222,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in JAZZ. UMB Bank n.a. raised its holdings in shares of Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 129 shares in the last quarter. GAMMA Investing LLC lifted its position in Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 121 shares during the last quarter. Itau Unibanco Holding S.A. lifted its position in Jazz Pharmaceuticals by 63.2% in the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after acquiring an additional 172 shares during the last quarter. Venturi Wealth Management LLC grew its holdings in shares of Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after purchasing an additional 704 shares during the last quarter. Finally, Versant Capital Management Inc grew its holdings in shares of Jazz Pharmaceuticals by 56.7% during the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock worth $119,000 after purchasing an additional 350 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $120.07 on Friday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a 50-day simple moving average of $122.60 and a 200-day simple moving average of $116.32. The company has a market capitalization of $7.26 billion, a PE ratio of 16.91, a P/E/G ratio of 0.90 and a beta of 0.56.

Analysts Set New Price Targets

A number of brokerages recently issued reports on JAZZ. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. TD Cowen lowered their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Piper Sandler reiterated an “overweight” rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Needham & Company LLC reissued a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $177.00.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. This represents a 0.35 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last three months, insiders sold 5,053 shares of company stock worth $617,442. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.